• eTheRNA
  • Developing safe, convenient and effective mRNA immunotherapies for the patient

Breast cancer

eTheRNA plans to run a clinical study with an in vivo, injectable TriMix-mRNA product in triple-negative breast cancer patients.

Triple-negative breast cancer means that the breast cancer cells test negative for the hormone receptors estrogen receptors (ER-) and progesterone receptors (PR-) as well as for HER2 (HER2-). Therefore, triple-negative breast cancer does not respond to hormonal therapy (such as tamoxifen or aromatase inhibitors) nor to therapies that target HER2 receptors, such as Herceptin (chemical name: trastuzumab).

An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, approximately 170000 are found to be triple negative. While the overall 5-year survival rate for breast cancer is now 90%, the 5-year survival rate for the TNBC subgroup is estimated around 75%.

Triple-negative breast cancers more likely to affect (a) younger people, before age 40 or 50, (b) African-American and Hispanic women, and (c) people with a BRCA1 mutation. Triple-negative breast cancer:

  • tends to be more aggressive than other types of breast cancer;
  • is characterized by lower five-year survival rates than for other types of breast cancer;
  • tends to be higher grade than other types of breast cancer at the time of diagnosis.
  • Like other forms of breast cancer, triple negative breast cancer is treated with surgery, radiation therapy, and/or chemotherapy. There is growing evidence that it might be possible to treat this type of breast cancer with immunotherapy.